BRPI0821683B8 - uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz - Google Patents

uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz

Info

Publication number
BRPI0821683B8
BRPI0821683B8 BRPI0821683A BRPI0821683A BRPI0821683B8 BR PI0821683 B8 BRPI0821683 B8 BR PI0821683B8 BR PI0821683 A BRPI0821683 A BR PI0821683A BR PI0821683 A BRPI0821683 A BR PI0821683A BR PI0821683 B8 BRPI0821683 B8 BR PI0821683B8
Authority
BR
Brazil
Prior art keywords
agonist
sympathetic
farsightedness
myopia
astigmatism
Prior art date
Application number
BRPI0821683A
Other languages
English (en)
Inventor
Sharma Anant
Original Assignee
Sharma Anant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sharma Anant filed Critical Sharma Anant
Publication of BRPI0821683A2 publication Critical patent/BRPI0821683A2/pt
Publication of BRPI0821683B1 publication Critical patent/BRPI0821683B1/pt
Publication of BRPI0821683B8 publication Critical patent/BRPI0821683B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou um agonista simpatético. é descrito um medicamento para administração tópica no olho de um humano ou animal que compreende pelo menos dois agentes farmacologicamente ativos. um dos agentes ativos é um agonista parassimpatético, tal como pilocarpina, e o outro agente ativo é tanto um antagonista simpatético tal como dapiprazol quanto timoxamina, ou um agonista simpatético tais como brimonidina ou iopidina. o medicamento é preferivelmente na forma de uma composição líquida, tais como gotas, um gel ou unguento para olho, e pode compreender uma composição de liberação lenta. o medicamento age para aumentar a acuidade visual por um período de diversas horas, e pode ser benéfico nos casos de presbiopia, miopia, hipermetropia, astigmatismo e/ou visão noturna prejudicada.
BRPI0821683A 2007-12-15 2008-12-15 uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz BRPI0821683B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0724558.2A GB0724558D0 (en) 2007-12-15 2007-12-15 Optical correction
PCT/GB2008/004129 WO2009077736A2 (en) 2007-12-15 2008-12-15 Optical correction

Publications (3)

Publication Number Publication Date
BRPI0821683A2 BRPI0821683A2 (pt) 2015-06-16
BRPI0821683B1 BRPI0821683B1 (pt) 2019-11-05
BRPI0821683B8 true BRPI0821683B8 (pt) 2021-05-25

Family

ID=39048209

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821683A BRPI0821683B8 (pt) 2007-12-15 2008-12-15 uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz

Country Status (10)

Country Link
US (4) US20090156606A1 (pt)
EP (3) EP2242487B1 (pt)
CN (1) CN101969940A (pt)
AU (1) AU2008337350A1 (pt)
BR (1) BRPI0821683B8 (pt)
CA (1) CA2747095C (pt)
ES (2) ES2572750T3 (pt)
GB (1) GB0724558D0 (pt)
WO (1) WO2009077736A2 (pt)
ZA (1) ZA201005026B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
WO2013041967A2 (en) 2011-09-20 2013-03-28 Altavista Instituto De Investigation Medica S.A.S Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
WO2018054489A1 (en) 2016-09-23 2018-03-29 Hallboeoek Finn Pharmacological treatment of myopia
JP7274475B2 (ja) 2017-07-20 2023-05-16 セインダ ファーマシューティカル グアンジョウ コーポレイション 近視の処置のための組成物および方法
MX2020004666A (es) * 2017-11-17 2022-01-26 Cellix Bio Private Ltd Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
NZ763699A (en) * 2017-11-17 2022-05-27 Cellix Bio Private Ltd Compounds, compositions and methods for treatment of eye disorders and skin diseases
KR20230079489A (ko) 2018-04-24 2023-06-07 알러간, 인코포레이티드 안구 증상의 치료를 위한 필로카르핀 염산염의 용도
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
AU2019360953A1 (en) * 2018-10-15 2021-05-13 Ocuphire Pharma, Inc. Methods and compositions for treatment of glaucoma and related conditions
KR20210096096A (ko) * 2018-10-26 2021-08-04 오큐파이어 파마, 인크. 노안, 산동, 및 기타 안구 장애의 치료를 위한 방법 및 조성물
US20200297720A1 (en) * 2019-03-22 2020-09-24 Baradaina LLC Methods of Treating Eye Disorders
EP3965732A4 (en) * 2019-05-08 2023-06-14 Harrow IP, LLC PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA AND PROCESS FOR THEIR PREPARATION
CN114585365A (zh) * 2019-06-10 2022-06-03 视觉治疗股份有限公司 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点
WO2020252061A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects
MX2020012116A (es) * 2020-11-12 2022-08-09 Cesar Alejandro Sanchez Galeana Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia.
CN117529316A (zh) * 2021-04-23 2024-02-06 奥库菲尔制药股份有限公司 用于治疗瞳孔散大、青光眼和其他眼部病症的方法和组合物
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883225A (en) * 1972-11-06 1975-05-13 Donald S Rehm Methods and apparatus for treating acquired myopia and similar or related eye conditions
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
EP0648118A1 (en) * 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6268359B1 (en) * 1998-01-28 2001-07-31 Senju Pharmaceutical Co., Ltd. Preventives or remedies for vision disorders
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20040116524A1 (en) * 2002-02-04 2004-06-17 Cohen Ben Z. Method of administering opthalmic fluids
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
WO2005051328A2 (en) * 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US7479277B2 (en) * 2005-02-24 2009-01-20 Wisconsin Alumni Research Foundation Method for reducing intraocular pressure using integrin-linked kinase inhibitor
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
PT1938839E (pt) 2006-12-18 2009-09-30 Jorge Luis Benozzi Composições oftálmicas de estimulantes parassimpáticos e anti-inflamatórios para utilização no tratamento de presbiopia
RU2009128703A (ru) 2006-12-26 2011-02-10 Клт Плаг Диливери, Инк. (Us) Имплантаты, доставляющие лекарства, для уменьшения оптических дефектов
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia

Also Published As

Publication number Publication date
WO2009077736A3 (en) 2009-12-30
US20090156606A1 (en) 2009-06-18
ES2572750T3 (es) 2016-06-02
WO2009077736A4 (en) 2010-02-25
BRPI0821683B1 (pt) 2019-11-05
ZA201005026B (en) 2011-03-30
US11278545B2 (en) 2022-03-22
CA2747095C (en) 2020-02-18
BRPI0821683A2 (pt) 2015-06-16
US20130096131A1 (en) 2013-04-18
EP3031457B1 (en) 2019-02-06
US8829037B2 (en) 2014-09-09
US20140378519A1 (en) 2014-12-25
EP3031457A1 (en) 2016-06-15
EP3505169B1 (en) 2021-11-03
EP3505169A1 (en) 2019-07-03
GB0724558D0 (en) 2008-01-30
CA2747095A1 (en) 2009-06-25
EP2242487B1 (en) 2016-02-24
AU2008337350A1 (en) 2009-06-25
WO2009077736A2 (en) 2009-06-25
EP2242487A2 (en) 2010-10-27
US20170216281A1 (en) 2017-08-03
US9623007B2 (en) 2017-04-18
CN101969940A (zh) 2011-02-09
ES2725002T3 (es) 2019-09-18

Similar Documents

Publication Publication Date Title
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
WO2012136969A3 (en) Ophthalmic treatments
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
EA202091999A3 (ru) Применение ингибиторов dpp iv
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
WO2008154368A3 (en) Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
SMT201300101B (it) Un'emulsione del tipo acqua in olio per il trattamento di una malattia dell'occhio
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
MX364378B (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
US20190374491A1 (en) Topical preparation for pain relief
JP2021107464A (ja) 眼科組成物
EA201291335A1 (ru) Фармацевтические композиции для местного применения
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
US20140228338A1 (en) Topical ocular analgesic agents
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
CA3126226A1 (en) Aceclofenac and betamethasone synergic pharmaceutical composition for the treatment of pain caused by rheumatic diseases or post-surgical pain
BRPI0920492A2 (pt) uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF